Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Chemoradiation in Rectal Cancer
NCT02586610Phase 2Withdrawn
- Sponsor
- Outcomes4Me
- Start
- Oct 2016
- Primary completion
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in rectal cancer, sponsored by Outcomes4Me. Planned start Oct 2016; status: withdrawn.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02586610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586610.